相关实验视频
Updated: Feb 26, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.4K
通过升级到下一代传感器来提高自动化胰岛素输送系统的用户体验
Pilar Isabel Beato-Víbora1, Estela Gil-Poch2, Francisco Javier Arroyo-Díez2
1Endocrinology and Nutrition Department, Badajoz University Hospital, Extremadura University, Badajoz, Spain.
Diabetes & vascular disease research
|February 25, 2026
概括
在自动化胰岛素输送系统 (AID) 中升级传感器显著改善了用户满意度和血糖控制. 这种增强导致1型糖尿病患者的传感器使用增加和在自动化模式中的时间增加.
科学领域:
- 内分泌学 在内分泌学.
- 生物医学工程 生物医学工程
- 糖尿病 技术 技术
背景情况:
- 用户满意度是自动化胰岛素输送 (AID) 系统的关键.
- 在传感器升级后评估满意度变化对于系统优化至关重要.
研究的目的:
- 在MiniMedTM-780G AID系统中从Guardian-Sensor®4升级到Simplera-SyncTM后,评估用户满意度的变化.
主要方法:
- 与91名1型糖尿病参与者进行前性干预研究.
- 在基线和升级后3个月使用葡萄糖监测经验问卷 (GME-Q) 评估用户满意度.
- 比较血糖控制指标和系统使用情况.
主要成果:
- 全球GME-Q得分显著改善 (3.84至4.40),所有分级 (有效性,方便性,侵入性) 都显示出增强.
- 传感器使用率从93%增加到98%,自动模式的时间从94%增加到100%.
- 观察到中度低血糖和整体低血糖事件的减少.
结论:
- 在AID系统中升级到新的传感器可以提高用户的满意度.
- 新的传感器可以增加传感器利用率和自动化模式持续时间.
- 通过传感器技术的进步,可以改善用户体验和血糖控制.
相关概念视频
Insulin Formulations: Types and Delivery
871
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
871
Insulin: Dosing Regimen and Adverse Effects
935
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
935
Modified-Release Drug Delivery Systems: Rate-Programmed II
50
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
50
Modified-Release Drug Delivery Systems: Rate-Programmed I
46
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
46
Insulin: Biosynthesis, Chemistry, and Preparation
1.6K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.6K
Modified-Release Drug Delivery Systems: Stimuli-Activated
53
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
53

